ClinicalTrials.gg
Active, not recruitingNCT05645380NeoTRACTUpdated Apr 28, 2026

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

A Phase 2 interventional study of Carboplatin and Docetaxel in Triple Negative Breast Cancer and Breast Cancer, sponsored by University of Kansas Medical Center. Active, not recruiting at 7 sites in United States. Open to female participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by University of Kansas Medical Center · Phase 2, Interventional, and Treatment

How we know · 11 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
139
Allocation
Non-randomized
Ages
18 Years to 120 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies testing carboplatin in Triple Negative Breast Neoplasms — 16 open to participants now, 29 under way, 5 of them phase 3. Carboplatin · Triple Negative Breast Neoplasms.

Planned enrollment
14th of 56
139 · median 52
Started
2022
with 2 others
Phase 2
43 of 56
16 open now
Primary completion
2026-12
later than 15 of 28 live
Registered
42nd of 56
by date

Among the 56 studies testing carboplatin in Triple Negative Breast Neoplasms, this one is the 14th largest by planned enrollment, is one of 3 that started in 2022, is one of 43 in phase 2, reaches primary completion later than 15 of the 28 other live ones, and was the 42nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

16 of the 56 studies testing carboplatin in Triple Negative Breast Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About carboplatin

Carboplatin: first FDA approval 1989 (PARAPLATIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 120 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies testing carboplatin in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.

Read the detailed description

Triple negative breast cancers (TNBC) with enrichment of immune system cells in and around the tumor are more sensitive to chemoimmunotherapy and have better prognosis. Imaging is often used during the course of neoadjuvant chemoimmunotherapy to monitor how the disease is responding to treatment, and disappearance of a patient's tumor on imaging after chemoimmunotherapy usually means that the tumor will have completely disappeared when the patient goes for surgery. This study will test whether the presence of immune system cells in and around the tumor and the response of the tumor on MRI can be used to personalize the type and amount of neoadjuvant chemoimmunotherapy for patients with TNBC.

03

Conditions studied

  • Triple Negative Breast Cancer
  • Breast Cancer

Keywords

  • Tumor infiltrating lymphocytes
  • Neoadjuvant chemotherapy
  • Neoadjuvant immunotherapy
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written
  • Female subjects 18 years of age or older
  • confirmed cT1c-T3N0, cT1-T3N1-N2, cTxN1-2 TNBC

    • The invasive tumor must be hormone receptor poor, defined as both estrogen receptor (ER) and progesterone receptor staining in ≤ 10% of invasive cancer cells by IHC
    • The invasive tumor must be -negative based on the current ASCO-CAP guidelines
  • No previous ipsilateral breast surgery for the current breast cancer
  • No previous chemotherapy, immunotherapy, endocrine therapy, or radiotherapy for the current breast cancer
  • Performance Status 0 - 1 documented within 21 days prior to the start of study treatment
  • Breast and axillary imaging (including ultrasound and MRI) within 42 days (6 weeks) prior to treatment initiation
  • Subjects with clinically and/or radiographically abnormal axillary or internal mammary lymph nodes should have pathologic confirmation of disease status with image-guided or fine needle aspiration
  • Archival breast tumor tissue has been obtained or has been requested for use
  • No clinically apparent disease. Staging to rule out metastatic disease is suggested for patients with clinical TNM stage III disease
  • Subjects with bilateral synchronous TNBC are eligible if they meet other eligibility criteria
  • No baseline neuropathy greater than grade 2
  • Patients are not pregnant, not breastfeeding, and either not a woman of or agrees to follow specific guidelines during the treatment period and for at least 120 days after the last dose of study treatment
  • Adequate hematologic, hepatic, and renal function assessed ≤ 21 days from treatment initiation
  • Only if assigned to Regimen C, ≥ 50% by echocardiogram or MUGA scan, per standard of care (assessed within 120 days prior to receiving doxorubicin + cyclophosphamide)

Exclusion criteria

Exclusion Criteria:

  • Current or anticipated use of other agents while participating in this study
  • Subject has previously received chemotherapy, immunotherapy, endocrine therapy, radiotherapy, or surgery for this breast cancer
  • Subject has clinically or radiographically detected disease
  • Subject has inflammatory breast cancer
  • Subject has a prior or concurrent whose natural history or treatment (in the opinion of the treating physician) has the potential to interfere with the safety or efficacy assessment of the treatment regimen. Note: Patients with squamous cell or basal cell carcinoma of the skin, ductal carcinoma in situ (DCIS) of the breast, or carcinoma in situ (CIS) of the uterine cervix who have undergone definitive therapy are not excluded from participation
  • History of allergic reactions attributed to doxorubicin, cyclophosphamide, carboplatin, or docetaxel
  • History of severe (≥ grade 3) to pembrolizumab or any of its
  • Prior treatment with an , anti-PD-L1, anti-PD-L2 inhibitor or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA4, OX40, CD137)
  • If participant has received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
  • Subject has received a within 30 days prior to treatment initiation
  • Subject is currently receiving treatment or has received treatment with an investigational agent within four weeks prior to treatment initiation, or has used an investigational device within four weeks prior to treatment initiation
  • Has a diagnosis of immunodeficiency or is receiving chronic therapy (in doses exceeding 10 mg daily prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of pembrolizumab
  • Active disease that has required systemic treatment (e.g., disease-modifying agents, corticosteroids, immunosuppressive drugs) in the past two years. Note: Patients using replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid therapy) are eligible
  • Currently has or has history of (within the past one year) non-infectious pneumonitis requiring steroids
  • Active infection requiring systemic therapy
  • Known history of (HIV) infection
  • Active (defined as HBsAg reactive) or (detectable HCV RNA)
  • History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of this study, interfere with the subject's participation for the full duration of the study, or it is not in the best interest of the subject to participate, in the opinion of the treating investigator
  • Subject has known psychiatric or substance abuse disorder(s) that would interfere with cooperation with the requirements of the study
  • Subject is pregnant or breastfeeding or expecting to conceive within the projected duration of the study, starting with the screening visit through 120 days after the last dose of trial treatment
  • Inadequate hematologic, renal, hepatic, or cardiac function.
  • Myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke, or within the past 12 months, uncontrolled hypertension (systolic BP > 160 mmHg, diastolic BP > 90 mmHg), uncontrolled or symptomatic arrhythmia, or greater than grade 2 peripheral vascular disease
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
139 participants (estimated)

Study arms

  • Active comparator
    High sTILs (≥30%)

    Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles.

    Drug: Carboplatin · Drug: Docetaxel · Drug: Pembrolizumab

  • Active comparator
    Intermediate sTILs (5-29%)

    Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for six cycles.

    Drug: Carboplatin · Drug: Docetaxel · Drug: Pembrolizumab

  • Active comparator
    Low sTILs (<5%)

    Carboplatin (AUC=6) + Docetaxel (75 mg/m2) + Pembrolizumab (200 mg) every 21 days for four cycles followed by Doxorubicin (60 mg/m2) + Cyclophosphamide (600 mg/m2) + Pembrolizumab (200 mg) every 14 or 21 days for four cycles.

    Drug: Carboplatin · Drug: Docetaxel · Drug: Doxorubicin · Drug: Cyclophosphamide · Drug: Pembrolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate in high sTIL cohort with radiographic complete response

    Defined as percentage of participants who achieve pathological complete response in the breast and axilla. Pathological complete response is defined as no evidence of invasive disease in the breast (residual DCIS permitted) and axilla at the time of pathology review.

    Time frame: Up to 26 weeks

Secondary outcomes

  1. Residual cancer burden (RCB) 0+1 rate in high sTIL cohort with radiographic complete response

    Defined as summed percentage of participants with RCB=0 and RCB=1 in the breast and axilla. Residual cancer burden score for each patient is calculated using surgical pathology parameters using an online tool (http://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3).

    Time frame: Up to 26 weeks

  2. pCR and RCB 0+1 in intermediate sTIL cohort

    Percentage of participants with intermediate sTILs who achieve pCR (RCB=0) and RCB=0+RCB=1.

    Time frame: Up to 26 weeks

  3. pCR and RCB 0+1 in low sTIL cohort

    Percentage of participants with low sTILs who achieve pCR (RCB=0) and RCB=0+RCB=1.

    Time frame: Up to 32 weeks

  4. Recurrence-free, event-free, and overall survival

    Recurrence-free survival is defined as the time from diagnosis to first recurrence (invasive ipsilateral breast, invasive local/regional, or distant), or to death as a result of any cause., event-free survival is defined as time from diagnosis to first recurrence (invasive ipsilateral breast, invasive local/regional, or distant), or to breast cancer related death, and overall survival is defined as time from diagnosis to death from any cause.

    Time frame: Up to 5 years

07

Study locations

7 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2026, 48 months after the start.

Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 48 months is below that.

Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartActual
Dec 5, 2022
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05645380
Responsible party
Sponsor
First posted
Dec 9, 2022
Start date
Dec 5, 2022
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 28, 2026

Study contacts

Priyanka Sharma, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carboplatin · Docetaxel · Doxorubicin · Cyclophosphamide · Pembrolizumab

Start the discussion